A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations

NCT ID: NCT01568749

Last Updated: 2014-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-12-31
• Study Completion Date: 2009-08-31

Brief Summary

A study investigating the pharmacokinetic profiles of four extended release paracetamol formulations

Conditions

Analgesia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: DOUBLE

Study Groups

Standard paracetamol

Marketed formulation

Group Type: ACTIVE_COMPARATOR

Paracetamol

Intervention Type: DRUG

Paracetamol

Formulation 1

Paracetamol formulation 1

Group Type: EXPERIMENTAL

Paracetamol formulation 1

Intervention Type: DRUG

Paracetamol

Formulation 2

Paracetamol formulation 2

Group Type: EXPERIMENTAL

Paracetamol Formulation 2

Intervention Type: DRUG

Paracetamol

Formulation 3

Paracetamol formulation 3

Group Type: EXPERIMENTAL

Paracetamol formulation 3

Intervention Type: DRUG

Paracetamol

Formulation 4

Paracetamol formulation 4

Group Type: EXPERIMENTAL

Paracetamol formulation 4

Intervention Type: DRUG

paracetamol

Interventions

Paracetamol

Paracetamol

Intervention Type: DRUG

Paracetamol formulation 1

Paracetamol

Intervention Type: DRUG

Paracetamol Formulation 2

Paracetamol

Intervention Type: DRUG

Paracetamol formulation 3

Paracetamol

Intervention Type: DRUG

Paracetamol formulation 4

paracetamol

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Consent:Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
• Age:Aged 18 to 50 years inclusive.
• Body Mass Index (BMI):Body Mass Index must be in the range 19 - 28 kg/m2.
• Compliance:Understands and is willing, able and likely to comply with all study procedures and restrictions.
• General Health:Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination.
• Contraception:Females of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception.

Exclusion Criteria

• Pregnancy:Women who are pregnant or who have a positive serum pregnancy test.
• Breast-feeding:Women who are breast-feeding.
• Allergy/Intolerance:Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
• Clinical Study/Experimental Medication:a) Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit. b) Previous participation in this study.
• Substance abuse:Recent history (within the last 5 years) of alcohol or other substance abuse.
• Personnel:An employee of the sponsor or the study site or members of their immediate family.
• Disease: a) Current or recurrent disease that could affect the action, absorption or disposition of the study medication or clinical or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure). b) Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures.
• Vegetarians:Subjects who are vegetarian.
• Hepatitis and HIV Screening:Positive screening for Serum Hepatitis B Surface Antigen, Hepatitis C or Human Immunodeficiency Virus (HIV).
• Medications:Current (within 14 days of screening) or regular use of any prescription, OTC, herbal medicine or drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to dosing, (e.g. barbiturates, theophylline, cimetidine, or erythromycin).
• Smoking:Non-smokers of less than 3 months or current use of nicotine-containing products.
• Blood:Subject has donated or experienced significant blood loss within 56 days of Visit 2, donated plasma within 7 days of Visit 2, or has a hemoglobin value of = 12.0 g/dL.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

MDS Pharma Services ARIZONA

Phoenix, Arizona, United States

Countries

United States

Other Identifiers

A2750596

Identifier Type: -

Identifier Source: org_study_id